Valuation: Enimmune corporation

Market Cap 1.21B 37.53M 32.46M 30.31M 27.81M 52.3M 3.57B 53.13M 356M 140M 1.79B 141M 138M 5.92B P/E 2024
-11.3x
P/E 2025 -9.04x
Enterprise Value 1.16B 35.84M 31M 28.95M 26.55M 49.95M 3.41B 50.74M 340M 133M 1.71B 135M 132M 5.65B EV / Sales 2024
35.4x
EV / Sales 2025 29.7x
Free-Float
28.72%
Yield 2024 *
-
Yield 2025 -
1 week+7.69%
Current month+7.69%
1 month+2.13%
3 months-11.35%
6 months-15.37%
Current year-18.45%
1 week 15.55
Extreme 15.55
16.95
1 month 14.9
Extreme 14.9
17.1
Current year 14.9
Extreme 14.9
22.15
1 year 14.9
Extreme 14.9
23.9
3 years 14.65
Extreme 14.65
49.3
5 years 14.65
Extreme 14.65
75.3
10 years 14.49
Extreme 14.49
125
Manager TitleAgeSince
Chief Executive Officer - 2019-01-06
Chief Tech/Sci/R&D Officer - 2014-07-20
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member - 2020-06-16
Chairman - 2019-01-06
Director/Board Member - 2014-01-01
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+7.69%+2.75%-64.41% 37.53M
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+32.55%+72.63% 55.18B
-1.09%+32.96%+19.95%+499.45% 28.63B
+2.72%+3.41%-15.88%-4.90% 23.53B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
Average +3.46%+10.95%+47.89%+179.85% 26.36B
Weighted average by Cap. +4.36%+13.09%+49.47%+168.46%

Financials

2024 2025
Net sales 39.92M 1.24M 1.07M 998K 916K 1.72M 118M 1.75M 11.71M 4.6M 58.96M 4.64M 4.54M 195M 48.19M 1.49M 1.29M 1.21M 1.11M 2.08M 142M 2.11M 14.14M 5.55M 71.19M 5.6M 5.48M 235M
Net income -158M -4.88M -4.22M -3.94M -3.62M -6.8M -464M -6.91M -46.23M -18.15M -233M -18.32M -17.92M -769M -164M -5.09M -4.4M -4.11M -3.77M -7.09M -484M -7.21M -48.23M -18.93M -243M -19.11M -18.69M -803M
Net Debt -382M -11.83M -10.23M -9.56M -8.77M -16.49M -1.13B -16.75M -112M -44M -564M -44.42M -43.45M -1.87B -54.59M -1.69M -1.46M -1.37M -1.25M -2.36M -161M -2.39M -16.02M -6.29M -80.64M -6.35M -6.21M -267M
Logo Enimmune corporation
ENIMMUNE CORP. is a Taiwan-based biotechnology new drug company mainly engaged in the development, produce and distribution of new drugs. The Company's new drug products include biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The Company mainly conducts drug testing business, biotechnology service business, international trade business, western medicine wholesale and retail business. The product is Tuberculin PPD.
Employees
-
Date Price Change Volume
26-08-07 NT$16.80 0.00% 116,963
26-08-06 NT$16.80 +0.30% 72,704
26-08-05 NT$16.75 +3.72% 84,720
26-08-04 NT$16.15 +0.31% 18,519
26-08-03 NT$16.10 +3.21% 69,613
  1. Stock Market
  2. Stocks
  3. 6564 Stock